N-[(4-chlorophenyl)methyl]guanidine

Compound number
MolPort-011-277-486
CAS number
46123-83-5
IUPAC
N-[(4-chlorophenyl)methyl]guanidine
IUPAC traditional
N-[(4-chlorophenyl)methyl]guanidine
SMILES
NC(=N)NCc1ccc(Cl)cc1
InChI key
CYYQVFZVCJFKES-UHFFFAOYSA-N
Molecular formula
Molecular weight
183.64
DMSO Solubility
Not known

Marketplace Offers

BLD Pharmatech (made-to-order)

Direct S&H to USA:
90.00 USD
Catalog
Building blocks
Ships out
25 business days
Purity
95%
Last updated
today
In warehouse
Unverified

Supplier Catalogue Data

Pack size Ships out Price Quantity
1 g November 8, 2022 404.00 USD
Add to Cart Buy
5 g November 8, 2022 1174.00 USD
Add to Cart Buy

MedChemExpress (made-to-order)

Direct S&H to USA:
50.00 USD
Catalog
Building blocks
Ships out
20 business days
Purity
>98%
Last updated
this month
In warehouse
Unverified

Supplier Catalogue Data

Pack size Ships out Price Quantity
100 mg November 1, 2022 706.20 USD
Add to Cart Buy
250 mg November 1, 2022 735.90 USD
Add to Cart Buy
500 mg November 1, 2022 767.80 USD
Add to Cart Buy

Get your compounds in the right format

Molport Reweighting and Reformatting Services

More Information

Compound identifiers

Compound number
MolPort-011-277-486
CAS number
46123-83-5

Names, Synonyms and 3rd Party Identifiers

Name
1-(4-Chlorobenzyl)guanidine
1-[(4-chlorophenyl)methyl]guanidine
N-(4-Chloro-benzyl)-guanidine
N-(4-chlorobenzyl)guanidine
guanidine, N-[(4-chlorophenyl)methyl]-
MFCD01724368

InChI

InChI
1/C8H10ClN3/c9-7-3-1-6(2-4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)
InChI key
CYYQVFZVCJFKES-UHFFFAOYSA-N

Formula

Molecular formula
C8H10ClN3
Molecular weight
183.64

Molport Guarantee

When you purchase products through the Molport website from any seller other than Molport itself, you will be protected by the Molport Guarantee. If you purchase products from Molport itself, this Molport Guarantee will not apply, and your remedies will be governed by the Molport Terms of Sale and Supply.

We use cookies to improve your experience on our websites and for advertising. By clicking "Accept All", you consent to our use of cookies. Learn more.

Feedback